BCR and neoplasm: While no overall changes of BCR and TCR diversities were found (Additional file 1: Figure S3G), tumor samples from patients treated with RUX + PAC run-in therapy showed significantly decreased BCR but not TCR diversity (Fig. 4K and Additional file 1: Figure S3H).